Patient-reported outcomes in DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer treated with nivolumab: CheckMate 142

被引：0

作者：

Michael, Overman ^{[1
]}

Shital, Kamble ^{[2
]}

Rebecca, Moss ^{[2
]}

Fiona, Taylor ^{[3
]}

Gregory, Maglinte ^{[2
]}

James, Shaw ^{[2
]}

Kim, Cocks ^{[3
]}

Erin, Mann ^{[3
]}

Christine, Yip ^{[3
]}

Thierry, Andre ^{[4
]}

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Bristol Myers Squibb, Lawrence Township, NJ USA

[3] Adelphi Values, Boston, MA USA

[4] Hop St Antoine, AP HP, Paris, France

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-308

引用

页数：2

共 50 条

[1] Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.
Overman, Michael J.
Lonardi, Sara
Leone, Francesco
McDermott, Raymond S.
Morse, Michael A.
Wong, Ka Yeung Mark
Neyns, Bart
Leach, Joseph L.
Alfonso, Pilar Garcia
Lee, James J.
Hill, Andrew
Lenz, Heinz-Josef
Desai, Jayesh
Moss, Rebecca A.
Cao, Z. Alexander
Ledeine, Jean-Marie
Tang, Hao
Kopetz, Scott
Andre, Thierry
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[2] Microbiome analyses in patients with previously treated, deficient DNA mismatch repair/microsatellite instability-high metastatic colorectal cancer treated with nivolumab ± ipilimumab: CheckMate 142
Kopetz, Scott
Zagonel, Vittorina
Overman, Michael J.
McDermott, Ray
Morse, Michael A.
Chen, Franklin L.
Lee, James
Moss, Rebecca A.
Ling, Lilan
Greenfield, Alexander
Greenawalt, Danielle
Cao, Z. Alexander
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[3] Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study
Overman, Michael J.
Gelsomino, Fabio
Aglietta, Massimo
Wong, Mark
Limon Miron, Maria Luisa
Leonard, Gregory
Garcia-Alfonso, Pilar
Hill, Andrew G.
Cubillo Gracian, Antonio
Van Cutsem, Eric
El-Rayes, Bassel
McCraith, Stephen M.
He, Beilei
Lei, Ming
Lonardi, Sara
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
[4] Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Overman, Michael J.
McDermott, Ray
Leach, Joseph L.
Lonardi, Sara
Lenz, Heinz-Josef
Morse, Michael A.
Desai, Jayesh
Hill, Andrew
Axelson, Michael
Moss, Rebecca A.
Goldberg, Monica V.
Cao, Z. Alexander
Ledeine, Jean-Marie
Maglinte, Gregory A.
Kopetz, Scott
Andre, Thierry
[J]. LANCET ONCOLOGY, 2017, 18 (09): : 1182 - 1191
[5] Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year followup from CheckMate 142
Andre, T.
Lonardi, S.
Wong, K.
Lenz, H.
Gelsomino, F.
Aglietta, M.
Morse, M.
Van Cutsem, E.
McDermott, R.
Hill, A.
Sawyer, M.
Hendlisz, A.
Neyns, B.
Abdullaev, S.
Memaj, A.
Lei, M.
Kopetz, S.
Overman, M.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S213 - S214
[6] Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer
Advani, Shailesh M.
Shi, Quilling
Overman, Michael J.
Loree, Jonathan M.
Lam, Michael
Morris, Van
Shureiqi, Imad
Kee, Bryan
Dasari, Arvind
Vilar, Eduardo
Sarshekeh, Amir Mehrvarz
Lin, Huei K.
Manue, Shanequa
Hamilton, Stan
Raghav, Kanwal
Maru, Dipen
Kopetz, Scott
Wang, Xin Shelley
[J]. CLINICAL COLORECTAL CANCER, 2020, 19 (01) : 48 - +
[7] Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
Lonardi, S.
Andre, T.
Wong, K. Y. M.
Morse, M.
McDermott, R.
Hill, A.
Hendlisz, A.
Lenz, H.
Leach, J.
Moss, R. A.
Cao, Z. A.
Ledeine, J.
Kopetz, S.
Overman, M.
[J]. ANNALS OF ONCOLOGY, 2017, 28 : 3 - 3
[8] First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
Lenz, Heinz-Josef
Van Cutsem, Eric
Limon, Maria Luisa
Wong, Ka Yeung Mark
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Luppi, Gabriele
Cardin, Dana B.
Dragovich, Tomislav
Shah, Usman
Abdullaev, Sandzhar
Gricar, Joseph
Ledeine, Jean-Marie
Overman, Michael James
Lonardi, Sara
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 161 - +
[9] Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Overman, Michael J.
Lonardi, Sara
Wong, Ka Yeung Mark
Lenz, Heinz-Josef
Gelsomino, Fabio
Aglietta, Massimo
Morse, Michael A.
Van Cutsem, Eric
McDermott, Ray
Hill, Andrew
Sawyer, Michael B.
Hendlisz, Alain
Neyns, Bart
Svrcek, Magali
Moss, Rebecca A.
Ledeine, Jean-Marie
Cao, Z. Alexander
Kamble, Shital
Kopetz, Scott
Andre, Thierry
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 773 - +
[10] Combination of nivolumab (nivo) plus ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.
Andre, Thierry
Lonardi, Sara
Wong, Ka Yeung Mark
Morse, Michael
McDermott, Raymond S.
Hill, Andrew Graham
Hendlisz, Alain
Lenz, Heinz-Josef
Leach, Joseph W.
Moss, Rebecca Anne
Cao, Z. Alexander
Ledeine, Jean-Marie
Chan, Emily
Kopetz, Scott
Michael, J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →